Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

Ho, David D.; McKeating, Jane A.; Li, Xi Ling; Moudgil, Tarsem; Daar, Eric S.; Sun, N. C.; Robinson, James E.

doi:10.1128/jvi.65.1.489-493.1991

Cited by 256 publications

(112 citation statements)

References 32 publications

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…During the course of HIV infection the exterior envelope glycoprotein, gp120, elicits NAb against virus. The most abundant NAb are CD4BS antibodies such as monoclonal antibodies F105, 15e, 21h, 1125h, and IgG1b12, which block gp120-CD4 interaction (17). Less common are CD4i antibodies such as monoclonal antibodies 48d and 17b, which disrupt the binding of gp120-CD4 complexes to chemokine receptors (18).…”

Section: Discussionmentioning

confidence: 99%

High level serum neutralizing antibody against HIV‐1 in Chinese long‐term non‐progressors

Wang

Shang

Han

et al. 2008

Microbiology and Immunology

View full text Add to dashboard Cite

NAb have been considered to be an important component of a protective immune response to HIV-1, yet the relationship between the capacity of HIV-1 NAb, the conserved neutralization epitopes and disease progression has been unclear. To gain a better understanding of the protective roles that NAb and conserved neutralization epitopes could play in LTNP, twenty-eight HIV-1-infected subjects were investigated by evaluation of the concentrations of HIV-1 NAb and conserved neutralization epitopes, using single-round PBMC neutralization assay and sequencing. Our study revealed that the concentration of NAb in LTNP was significantly higher than that in subjects with asymptomatic HIV (P < 0.05) and AIDS (P < 0.01). No amino acids substitutions were found in the conserved epitopes of the HIV-1 gp120 region in LTNP, whereas the viruses circulating both in persons with asymptomatic HIV and those with AIDS had amino acid substitutions in their conserved neutralization epitopes. This study suggests that high levels of NAb and stable epitopes in gp120 could play a crucial role in protection against disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%

High level serum neutralizing antibody against HIV‐1 in Chinese long‐term non‐progressors

Wang

Shang

Han

et al. 2008

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…27). The receptivity/permissiveness of HTLV-I or HTLV-II transformed (transactivated) lymphoid cells to HIV infection followed by rapid viral replication and release, combined with the formation of MNGCs as the culture time progresses (often together with a population of mitotic single uninfected and infected cells) has yielded valuable information on the nature of viral glycoprotein Gpl20, the cellular CD4 antigen and CD4~GpI20 interaction (Clapham et al, 1987;Harada et al, 1985;Hussey et al, 1988;Ho et al, 1991;Lifson et al, 1986aLifson et al, , 1986bMontefiori and Mitchell, 1987;Nara et al, 1987;Sodroski et al, 1986;Yoffe et al, 1987). There is here a clear parallel between the C-type retrovirally-transformed cultured lymphoid cells and the large transformed single lymphocytes seen in lymph node biopsy samples from AIDS patients (Byrnes et al, 1983), which often lie alongside MNGCs.…”

Section: A Multinucleate Giant Cells In Vivo and In Vitromentioning

confidence: 99%

The ultrastructure of multinucleate giant cells

Harris

1993

Micron

View full text Add to dashboard Cite

A survey of the available ultrastructural data on physiologically and pathologically occurring and virally-induced multinucleate giant cells (MNGCs) is presented. Emphasis is initially placed upon the bone osteoclast, the skeletal muscle myotube and the placental syncytiotrophoblast. The widespread occurrence of MNGCs in a range of pathological situations is discussed, with emphasis upon the broad involvement of the macrophage in inflammatory responses. Many viruses produce cell fusion in vivo and in vitro when cell cultures are infected. Several examples are given. A clear distinction is drawn between viral fusion from "without" and viral fusion from "within" the cell. The cytopathic effect (CPE) of the animal and human retroviruses is discussed in considerable detail. The in vivo and in vitro formation of lymphocytic and macrophage MNGCs by HIV-1 is given extensive coverage. The possible significance of the presence of brain MNGCs of macrophage/ microglial origin as a cellular feature of AIDS dementia is discussed. A new hypothesis is advanced relating to the possible role of endogenous C-type retrovirus in the physiological fusion of the invasive placental cytotrophoblasts to create the syncytiotrophoblast. The evolutionary and developmental significance of such an event in relation to the evolution of the placental mammals is discussed. The possible importance of MNGC formation in the depletion of the CD4 ÷ population of T-lymphocytes in vivo in the clinical progression of the AIDS-related complex and AIDS is related to the potent fusogenic effect of HIV-I when cell cultures are infected.

show abstract

“…The variable domains V1, V2 and V3 of gp120 have been suggested to be involved in HIV-1 fusion and infectivity at a stage subsequent to CD4 binding. Amino acid substitutions in and binding of mAbs directed against these domains affect syncytium formation and infectivity without affecting CD4 binding [65][66][67][68][69][70][71]. Gp120-CD4 interaction induces conformational changes in both CD4 and gp120 [72][73][74][75][76] but the significance of these conformational alterations for the subsequent fusion event remains undefined.…”

Section: Hiv-1 Envelope Proteins and Phenotype Variabilitymentioning

confidence: 99%

Molecular determinants of human immunodeficiency virus type I phenotype variability

Fouchier

Schuitemaker

1996

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract.The clinical course of HIV-1-infected individuals can be highly variable. Progression to AIDS can occur within 1 year after infection but symptom-free infection for more than 15 years has also been reported. This variation can either be determined by host factors, the biological variability of the virus or both. Here the molecular determinants and clinical relevance of HIV-1 biological phenotype variability are reviewed.

show abstract

Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

Cited by 256 publications

References 32 publications

High level serum neutralizing antibody against HIV‐1 in Chinese long‐term non‐progressors

High level serum neutralizing antibody against HIV‐1 in Chinese long‐term non‐progressors

The ultrastructure of multinucleate giant cells

Molecular determinants of human immunodeficiency virus type I phenotype variability

Contact Info

Product

Resources

About